Program

 

 

Day 1 - Monday, 28 September 2020

 

 

10:00 AM
EDT

Opening remarks

Jennifer Kiser, PharmD, PhD

Jennifer Kiser PharmD, PhD
University of Colorado - Denver, CO, USA

 

 Kimberly Scarsi, PharmD

 
Kimberly Scarsi PharmD, MS
University of Nebraska - Omaha, NE, USA

 
    
 

Session 1:  COVID-19 Session

 
 

10:10 AM
EDT

Emerging infections and Biosecurity
Mohammed Lamorde FRCP, PhD
Infectious Diseases Institute, Makerere University College Of Health Sciences, Uganda, Africa

 
 10:30 AM
EDT

Gulick, Roy (2) 2019 120x160

COVID-19 Treatment
Roy Gulick, MD, MPH
Weill Cornell Medicine - New York, USA

 
 10:50 AM
EDT

Owen, Andrew - 2019

Role of Pharmacology of Selection COVID-19 Candidates
Andrew Owen, BSc, MSc, PhD, FSB
University of Liverpool - Liverpool, UK

 
 11:10 AM
EDT
Gender neutral avatar 120x160
FDA Perspective on COVID-19
Kimberly Struble
Food & Drug Administration, Washington, USA
 
 11:30 AM
EDT
Faculty discussion 
    
 12:00 PM
EDT
Virtual Coffee Break | Meet Your Colleagues 
    
 Session 2:  Abstracts Session
 
 12:30 PM
EDT

Oral Abstract Presentations

 
  Steady-State Plasma TFV/FTC Among Adolescent Transgender Men and Women Receiving Directly Observed Daily TDF/FTC
Jenna Yager, University of Colorado, USA
 
  Plasma and Breastmilk Pharmacokinetics of Tenofovir Using Dried Blood and Breast Milk Spots in HIV Infected Postpartum Women in Uganda
Letisha Najjemba, Infectious Disease Institute, Uganda
 
  Time Course of Tenofovir-Diphosphate Carryover in DBS Following TDF to TAF Switch
Kristina Brooks, University of Colorado, USA
 
 01:00 PM
EDT
Live Q&A with Abstract Presenters 
    
 01:15 PM
EDT
Oral Poster Presentations 
  TFVdp/FTCtp Concentrations in Rectal Samples:  No Correlation Between Epithelial Cells Collected by Cytobrush and Isolated CD4+ Cells
Mackenzie Cottrell, UNC Eshelman School of Pharmacy, USA
 
  Mechanistic Modelling for the Quantitative Evaluation
Fazila Bunglawala, University of Liverpool, UK
 
  Intracellular EFdA Pharmacology Differs Between Species: Implications for Preclinical Study Design
Mackenzie Cottrell, UNC Eshelman School of Pharmacy, USA
 
  Inflammation Affects Antiretrovirals Plasma and Intracellular Exposure
Micol Ferrara, Ospedale Amedeo Di Savoia, Italy
 
 01:35 PM
EDT
Live Q&A with Abstract Presenters 
    
 01:45 PM
EDT
End of first day 
    
   Online Networking Opportunities & E-Poster Viewing 
    
  Online Networking | E-poster Viewing plus live chat with presenters 
 

Day 2 - Tuesday, 29 September 2020

 
 Session 3:  Management of New Antivirals
 
 10:00 AM
EDT

Pharmacology of bNABs
Edmund Capparelli, PharmD
University of California San Diego, San Diego, United States

 
 10:20 AM
EDT

Clinical Pharmacology Long Acting ARVs
Marta Boffito MD, PhD
Chelsea-Westminster Hospital, London, UK

 
 10:40 AM
EDT

Charles Flexner, MD

Development of Novel Formulations/Devices
Charles Flexner, MD
Johns Hopkins University School of Medicine, Baltimore, MD, USA

 
 11:00 AM
EDT

Faculty Discussion

 
    
 11:30 AM
EDT
Virtual Coffee Break | Meet Your Colleagues
 
    
 Session 4:  Abstracts Session
 
 12:00 PM
EDT

Oral Abstract Presentations - Population PK

 
  Population Pharmacokinetics of HIV-Specific Broadly Monoclonal Neutralizing Long-Acting Antibody, VRC01LS, in Term Infants
Jincheng Yang, University of California San Diego, USA
 
  In-Silico Prediction of Intramuscular Long-Acting Rilpivirine in Liver Impairment With PBPK Models
Nicolas Cottura, University of Liverpool, UK
 
 12:30 PM
EDT
Live Q&A with Abstract Presenters 
    
 12:25 PM
EDT

Oral Poster Presentations

 
  

Lack of a Pharmacokinetic (PK) Interaction Between HIV-1 Maturation Inhibitor (MI) GSK3640254 (GSK’254) and Oral Contraceptive (OC) Ethinyl Estradiol (EE)/Levonorgestrel Pbpk Models

Lack of a Pharmacokinetic (PK) Interaction Between HIV-1 Maturation Inhibitor (MI) GSK3640254 and Dolutegravir

Open-Label, Drug-Drug Interaction Study between HIV-1 Maturation Inhibitor (MI) GSK3640254 and Tenofovir Alafenamide (TAF)/Emtricitabine (FTC) in Healthy Participants
Teodora Pene Dumitrescu, Glaxosmithkline, USA

 
  Antiretroviral Drug-drug Interaction (DDI) Profile of Long-acting Cabotegravir and Rilpivirine
Parul Patel, ViiV Healthcare, USA
 
  Fostemsavir Drug-Drug Interaction Profile, an Attachment Inhibitor and Oral Prodrug of Temsavir, for Patients With Multidrug Resistant HIV-1 Infection
Katy Moore, ViiV Healthcare, USA
 
  Pharmacokinetics, Safety, and Tolerability of Single- and Multiple Ascending Doses of JNJ-64417184, a Non-Nucleoside Inhibitor of Respiratory Syncytial Virus Polymerase, in Healthy Volunteers
Mina Pastagia, Janssen Biopharma, USA
 
  Single-Ascending Dose (SAD) Pharmacokinetics of Hepatitis B Virus (HBV)-Specific JNJ-73763989 in Non-Japanese and Japanese Healthy Volunteers (HV)
Thomas Kakuda, Janssen Biopharma, USA
 
  Effect of Multiple-Dose Itraconazole on the Pharmacokinetics of Single-Dose JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy Volunteers
Joris Vandenbossche, Janssen Biopharma, USA
 
  01:00 PM
EDT
Live Q&A with Abstract Presenters 
    
 01:15 PM
EDT
End of second day 
    
   Online Networking Opportunities & E-Poster Viewing 
    
  Online Networking | E-poster Viewing plus live chat with presenters 
 

Day 3 - Wednesday, 30 September 2020

 
 Session 5:  Topic for Discussion
 
 10:00 AM
EDT

Arya, Vikram 2020 120x160

Perspectives on the Use of Endogenous Biomarkers to Assess Transporter Mediated Drug-Drug Interactions (DDIs)
Vikram Arya, PhD, FCP
Food and Drug Administration, Silver Spring, USA

 
 10:25 AM
EDT

Cattaneo, Dario 2019 120x160

Role of herbal in DDIs
Dario Cattaneo, PharmD, PhD
Luigi Sacco University Hospital, Milan, Italy

 
 10:50 AM
EDT

Faculty discussion

 
    
 11:05 AM
EDT
Virtual Coffee Break | Meet Your Colleagues
 
    
 Session 6:  Abstracts Session
 
 11:35 AM
EDT 
Oral Abstract Presentations - Special Populations - Pediatrics 
  Impact of CYP2B6 Genotype, TB Therapy and Formulation on Efavirenz Pharmacokinetics in Infants and Children Under 40 Months of Age
Mina Nikanjam, University of California San Diego, USA
 
  A Population Pharmacokinetic Analysis Assessing the Exposure of Raltegravir Once-Daily 1200mg in Pregnant Women Living With HIV
Vera Bukkems, Radboudumc, Netherlands
 
  Comparison of Relative Bioavailability of TIVICAY Neonatal Liquid Formulations to Pediatric Dispersible Tablets
Rajendra Singh, Glaxosmithkline, USA
 
 12:05 PM
EDT
Live Q&A with Abstract Presenters 
    
 12:20 PM
EDT

Oral Poster Presentations - Special Populations

 
  Ledipasvir PK-PD (Pharmacokinetics - Pharmacodynamics): Relationship between drug exposure and sustained virologic response rates in a cohort of patientsRelationship Between Drug Exposure and Sustained Virologic Response Rates in a Cohort of Patients
Omar Elsherif, Queen Elizabeth Hospital Birmingham, UK
 
  Exploring the Role of Age in Transporter-Related Drug-Drug Interactions
Hannah Kinvig, University of Liverpool, UK
 
  Genetic Associations With Weight Gain Among South Africans Who Initiated Dolutegravir- and Tenofovir-Containing Regimens in the ADVANCE Study
Zinhle Cindi, University of Cape Town, South Africa
 
  Rifabutin Pharmacokinetics and Safety Among TB/HIV Coinfected Young Children Receiving Lopinavir
Holly Rawizza, Brigham and Women's Hospital, USA
 
   Impact of Weekly Administration of Rifapentine and Isoniazid on Steady State Pharmacokinetics of Tenofovir Alafenamide in Healthy Volunteers: A Preliminary
Jomy George, National Institutes of Health, USA
 
  12:45 PM
EDT
 Live Q&A with Abstract Presenters 
    
  12:55 PM
EDT
Closure - Best of Abstracts Awards 
    
 01:00 PM
EDT
End of the Virtual Workshop